

GLP-RA Summary

- The link between diabetes and increased CVD risk is long established.
- However, CVD benefit of specific agents has been lacking until recently; i.e., SGLT inhibitors and GLP-RA.
- These agents should be considered first or second line in almost all diabetics.
- For obese patients with CHF, CVD, OSA, etc., they should also be prioritized.
- Unfortunately, access and affordability remain an issue.



1

Questions

- When do you discuss GLP-RA therapy with the following patient type?
 - Diabetic with other risk factors?
 - Established CVD?
 - Heart Failure?
 - HFrEF, HFpEF, or both?
 - Sleep apnea?



2